Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL therapies for cancer patients, has granted inducement stock options to 59 new non-executive employees. The grants, approved on May 15, 2025, cover 278,770 shares of common stock with an exercise price of $1.76 per share. These options were awarded under the company's Amended and Restated 2021 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
The stock options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining shares vesting quarterly over the following two years, contingent on continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA), un'azienda biotecnologica specializzata in terapie TIL per pazienti oncologici, ha concesso opzioni azionarie di incentivo a 59 nuovi dipendenti non esecutivi. Le concessioni, approvate il 15 maggio 2025, riguardano 278.770 azioni ordinarie con un prezzo di esercizio di 1,76 $ per azione. Queste opzioni sono state assegnate nell'ambito del Piano di Incentivazione Modificato e Ristabilito 2021 dell'azienda, in conformità con la Regola Nasdaq 5635(c)(4).
Le opzioni prevedono un piano di maturazione triennale, con un terzo delle azioni che maturano al primo anniversario di impiego e il resto che matura trimestralmente nei due anni successivi, a condizione di mantenere l'impiego.
Questo ampliamento della forza lavoro con 59 nuovi dipendenti indica una crescita aziendale significativa. Il piano di maturazione strutturato favorisce la fidelizzazione del personale per un periodo di 3 anni, mentre le opzioni azionarie allineano gli interessi dei dipendenti con le performance dell'azienda.
Iovance Biotherapeutics (NASDAQ: IOVA), una empresa biotecnológica especializada en terapias TIL para pacientes con cáncer, ha otorgado opciones sobre acciones de incentivo a 59 nuevos empleados no ejecutivos. Las concesiones, aprobadas el 15 de mayo de 2025, cubren 278,770 acciones ordinarias con un precio de ejercicio de $1.76 por acción. Estas opciones fueron otorgadas bajo el Plan de Incentivos Modificado y Restablecido 2021 de la compañía, conforme a la Regla de Listado Nasdaq 5635(c)(4).
Las opciones tienen un calendario de adquisición de derechos de tres años, con un tercio que se adquiere en el primer aniversario laboral y el resto que se adquiere trimestralmente durante los siguientes dos años, condicionado a la continuidad en el empleo.
La incorporación de 59 nuevos empleados refleja un crecimiento de la empresa. El calendario estructurado de adquisición ayuda a retener talento durante 3 años y las opciones sobre acciones alinean los intereses de los empleados con el desempeño de la compañía.
Iovance Biotherapeutics (NASDAQ: IOVA)는 암 환자를 위한 TIL 치료법을 전문으로 하는 바이오테크 회사로, 59명의 신입 비임원 직원에게 유인 주식 옵션을 부여했습니다. 이 부여는 2025년 5월 15일에 승인되었으며, 278,770주의 보통주에 대해 주당 $1.76의 행사가격이 적용됩니다. 이 옵션은 회사의 2021년 개정 및 재정립된 유인 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
주식 옵션은 3년간의 베스팅 일정이 있으며, 첫 번째 근무 기념일에 3분의 1이 베스팅되고, 나머지 주식은 이후 2년간 분기별로 베스팅되며 계속 근무 조건이 붙습니다.
59명의 신입 직원 채용은 회사의 성장세를 나타냅니다. 구조화된 베스팅 일정은 3년간 인재 유지를 돕고, 주식 옵션은 직원의 이익을 회사 성과와 일치시킵니다.
Iovance Biotherapeutics (NASDAQ: IOVA), une société de biotechnologie spécialisée dans les thérapies TIL pour les patients cancéreux, a accordé des options d'achat d'actions incitatives à 59 nouveaux employés non cadres. Les attributions, approuvées le 15 mai 2025, portent sur 278 770 actions ordinaires avec un prix d'exercice de 1,76 $ par action. Ces options ont été attribuées dans le cadre du Plan d'Incitation Modifié et Reformulé 2021 de la société, conformément à la règle Nasdaq 5635(c)(4).
Les options d'achat d'actions suivent un calendrier d'acquisition sur trois ans, un tiers devenant acquis au premier anniversaire d'emploi et le reste étant acquis trimestriellement au cours des deux années suivantes, sous réserve de la poursuite de l'emploi.
L'embauche de 59 nouveaux employés témoigne de la croissance de l'entreprise. Le calendrier structuré d'acquisition favorise la fidélisation des talents sur trois ans, tandis que les options alignent les intérêts des employés sur la performance de la société.
Iovance Biotherapeutics (NASDAQ: IOVA), ein Biotechnologieunternehmen, das sich auf TIL-Therapien für Krebspatienten spezialisiert hat, hat Anreizaktienoptionen an 59 neue nicht-exekutive Mitarbeiter vergeben. Die Zuteilungen, genehmigt am 15. Mai 2025, umfassen 278.770 Aktien mit einem Ausübungspreis von 1,76 $ pro Aktie. Diese Optionen wurden im Rahmen des geänderten und neu gefassten Anreizplans 2021 des Unternehmens vergeben und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen haben einen dreijährigen Vesting-Zeitplan, wobei ein Drittel am ersten Beschäftigungsjubiläum vestet und der Rest im Verlauf der folgenden zwei Jahre vierteljährlich vestet, vorausgesetzt die Beschäftigung wird fortgesetzt.
Die Erweiterung der Belegschaft um 59 neue Mitarbeiter signalisiert Wachstum des Unternehmens. Der strukturierte Vesting-Plan unterstützt die Bindung von Talenten über einen Zeitraum von 3 Jahren, während die Aktienoptionen die Interessen der Mitarbeiter mit der Unternehmensleistung in Einklang bringen.
- None.
- Potential dilution of existing shareholders' equity
- Additional compensation expenses for the company
SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 15, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 278,770 shares of Iovance’s common stock to 59 new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2023, February 26, 2024, and November 22, 2024, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
How many stock options did Iovance Biotherapeutics (IOVA) grant to new employees in May 2025?
What is the exercise price for IOVA's May 2025 inducement stock options?
What is the vesting schedule for Iovance's May 2025 inducement stock options?
How many new employees received stock options from IOVA in May 2025?
